Global Foundation Launches to Accelerate an End to Smoking
With the goal of eliminating smoking worldwide, the Foundation for a Smoke-Free World formally launched today in New York City. The Foundation is founded and led by Dr. Derek Yach, a renowned anti-smoking crusader who, while at the World Health Organization (WHO), was the primary architect of the WHO’s Framework Convention on Tobacco Control. The Foundation will build upon recent shifts in policy and science to fund research and support collaborative initiatives to accelerate progress in reducing harm and deaths from smoking worldwide.
“For decades, despite significant tobacco control initiatives, smoking has remained the world’s number one preventable cause of death. With more than one billion smokers, and one death every six seconds from smoking, there is an urgent need to accelerate progress and end this public health crisis,” said Dr. Yach, the Foundation’s founder and president-designate. “The Foundation for a Smoke-Free World will bring needed resources, expertise, fresh thinking, and a collaborative spirit to form partnerships, initiate dialogue, conduct research, and take actions to more rapidly rid the world of smoking and its negative health impacts.”
The Foundation has secured initial funding of approximately US$80 million annually over the next 12 years, beginning in 2018, from Philip Morris International (PMI). The Foundation is seeking and expects to receive funding from other sources as well. Importantly, the grant terms, bylaws, and non-profit status of the Foundation preclude PMI or other tobacco industry representatives from involvement in Foundation governance, or from having any influence over the Foundation’s funding decisions, strategy, or activities. The Foundation will have an independent research agenda, ownership of its data, freedom to publish, and strict protections against conflict of interest.
The Foundation’s ongoing activities and research priorities will be informed through a transparent public dialogue, and will be subject to the approval of an independent board of directors. Initial activities are expected to be focused in four areas of need:
- Support research into smoking harm reduction and build research capacity through academic centers of excellence
- Collaboratively build consensus around which interventions can best reduce harm and deaths from smoking and increase smoking cessation
- Measure and report on global progress towards smoking harm reduction
- Identify alternative crops and livelihoods for tobacco farmers as the global demand for tobacco declines
“The world needs to act with greater urgency and more creativity to cut the adult smoking rate and prevent cancer, heart disease and lung diseases,” said Dr. John Seffrin, professor of practice at Indiana University-Bloomington School of Public Health and past president of the Union for International Cancer Control. “The Foundation for a Smoke-Free World will bring new energy, needed resources and significant expertise to the fight. The Foundation will fund critical research to help eliminate gaps in science, and help the global community pick up the pace of progress in providing science-based solutions for the world’s one billion smokers, most of whom seek to quit cigarettes.”
The Foundation will also focus its efforts on understanding and helping to address disproportionate challenges and impacts associated with efforts to end smoking in developing countries. For example, the Foundation will work to help smallholder tobacco farmers shift to alternative crops.
“A decline in tobacco production creates an opportunity to solve food insecurity issues that exist in many parts of the world,” said Dyborn Chibonga, CEO of the National Smallholder Farmers’ Association of Malawi. “I look forward to helping the Foundation partner with public and private entities to develop practical solutions to these pressing problems.”
“It is time for new thinking and open, collaborative approaches that speed us closer to our shared goal,” said Dr. Yach. “We’ll need a multitude of approaches – encompassing behavioral and biological science, economics, policy, technology, pharmacology, epidemiology, and agricultural expertise – to develop the right approaches for different regions and cultures. If we work together, I’m confident we can end smoking throughout the world.”
For more information about the Foundation and its activities, or to review its bylaws and certificate of incorporation, please visit www.smoke-freeworld.org.
Editor’s note: Dr. Yach will formally announce the Foundation and outline its goals at 9:30 am EDT today, September 13, during a speech to the Global Tobacco & Nicotine Forum 2017 at the InterContinental New York Barclay in New York City. Dr. Yach will be preceded by Mitch Zeller, director of the US FDA's Center for Tobacco Products, who will speak at 8:45 am EDT about the need for a new approach to smoking cessation. Members of the media are invited to attend.
About the Foundation for a Smoke-Free World
The Foundation for a Smoke-Free World is an independent, non-profit organization dedicated to accelerating global efforts to reduce deaths and harm from smoking, with the ultimate goal of eliminating smoking worldwide. The Foundation also supports populations who are disproportionately burdened by a rapid transition away from smoking, with an initial focus on helping tobacco farmers in the developing world. For more information about the Foundation, please visit www.smoke-freeworld.org.
for The Foundation for a Smoke-Free World
Tom Langford, 617-761-6775
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
First Westinghouse AP1000® Nuclear Plant Sanmen 1 Completes Initial Criticality21.6.2018 23:24 | Tiedote
Westinghouse Electric Company, China State Nuclear Power Technology Corporation (SNPTC) announced today that the world’s first AP1000 nuclear power plant located in Sanmen, Zhejiang Province, China has successfully completed initial criticality. “Today we completed the final major milestone before commercial operation for Westinghouse’s AP1000 nuclear power plant technology,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. “We are one step closer to delivering the world’s first AP1000 plant to our customer and the world – with our customers, we will provide our customers in China with safe, reliable and clean energy from Sanmen 1.” Following initial criticality will be connection to the electrical grid. Once plant operations begin at Sanmen 1, it will be the first AP1000 nuclear power plant in operation, offering innovative passive safety system technology, multiple layers of defense and advanced controls for unequaled reliability and safety. Commentin
Westinghouse Loads Fuel in Second AP1000® Nuclear Power Plant21.6.2018 23:07 | Tiedote
Westinghouse Electric Company and its customers, China State Nuclear Power Technology Corporation (SNPTC) and Shangdong Nuclear Power Company Limited (SDNPC) announced today that Haiyang Unit 1, the AP1000 nuclear power plant located in Haiyang, Shandong Province, China, has begun to load fuel. “This is a great day for Westinghouse, our China partners and the nuclear industry. Haiyang Unit 1 continues to demonstrate our ability to deliver safe, innovative solutions for power generation,” said José Emeterio Gutiérrez, Westinghouse president and chief executive officer. He added, “Westinghouse will continue to deploy AP1000 technology throughout the world and demonstrate our technical leadership in the nuclear energy industry.” Fuel load at Haiyang Unit 1 commenced at 7:36 p.m. (GMT+8) today. Earlier this summer, in preparation for fuel load, Haiyang Unit 1 successfully completed the necessary testing and regulatory reviews conducted by China’s National Nuclear Safety Administration (NNS
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 21:23 | Tiedote
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo
Philip Morris International Makes Call to Creative, Media and Communications Communities21.6.2018 21:13 | Tiedote
Philip Morris International Inc. (“PMI”) (NYSE: PM), today announced a bold call to action for the creative, media and communications communities to embrace its ongoing commitment to creating a smoke-free world. As part of this initiative, PMI will offer smoke-free alternatives wherever we can, including heated tobacco products and e-cigarettes, to current smokers in the industry who would otherwise continue to smoke. During a keynote at the PMI Science Lounge at The Cannes Festival of Creativity, SVP of Communications Marian Salzman said, “We are asking the creative community to join us in raising awareness of the potential of science, technology and innovation for those who smoke and the people around them.” The move is part of PMI’s vision to lead the charge towards greater innovation and technology in the tobacco industry, all of which is backed by science. Agencies interested in joining the movement can contact Marian Salzman at email@example.com. “People who smoke deserve in
IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats21.6.2018 19:30 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces a Cyber Security Forum to expand its position as the preeminent cyber security destination for broadcasters and media. The event will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018, which last year attracted more than 57,000 attendees from 170 countries. The Cyber Security Forum is one-day, invitation-only event that will convene Chief Technology Officers, Chief Information Officers, Chief Information Security Officers and Chief Digital Officers within media and broadcasting for a conversation on the challenges and opportunities presented by cyber security for broadcasters. Attendees will discuss how to anticipate the next cyber threat, how to manage a breach and how to prepare for the future of cyber security. The Cyber Security Forum sits alongside the Telco & Media Innovation Forum and Leaders’ Forum as part of IBC’s Exec
Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe21.6.2018 19:23 | Tiedote
Mensia Technologies, french MedTech start up, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour. Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in Rennes are computing real time signaling softwares. The neurofeedback technique is non invasive, at home and without drugs. MENSIA KOALA treats ADHD, Attention Deficit Disorders with or without Hyperactivity, children and adolescents. This unique medical device is a therapeutic video game on an interactive tablet connected to the brain activity. Children learn to control their attention by exercising 3 times a week during 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme